On December 29, 2016, Regeneus entered into a partnership with AGC Asahi Glass (AGC), a major Japanese manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals, for “exclusive manufacture of Progenza stem cell technology for Japanese market.” According to Regeneus, the Progenza product is generated from expanded MSCs extracted from the adipose tissue and includes secretions from MSCs that enhance the viability and functionality of the cells during the freezing/thawing process.
RGS share price potential is much better than CYP.
Our current market cap is $34M
Millions fund coming
With good news, this will pave the way for the SP back to 50cents+.
[IMG] On December 29, 2016, Regeneus entered into a partnership...
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
